Effects of nalbuphine and meperidine on postoperative uterine contraction pain in patients undergoing artificial abortion or hysteroscopy under general anesthesia

Start Date30 Sep 2024

Sponsor / Collaborator-

ChiCTR2400089664 / RecruitingEarly Phase 1IIT

A Study Of The Effect Of Nalbuphine Preempative Analgesia In Laparoscopic Total Hysterectomy

Start Date12 Sep 2024

Sponsor / Collaborator

Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital)

100 Clinical Results associated with Nalbuphine Hydrochloride

100 Translational Medicine associated with Nalbuphine Hydrochloride

100 Patents (Medical) associated with Nalbuphine Hydrochloride

1,172

Literatures (Medical) associated with Nalbuphine Hydrochloride

31 Dec 2024·JOURNAL OF DERMATOLOGICAL TREATMENT

Association of pruritus and chronic cough: an all of us database study

Article

Author: Pulsinelli, Juliana ; Correa da Rosa, Joel ; Ungar, Benjamin ; Kim, Brian ; Wang, Zhen ; Sharma, Divija

PURPOSE:

Based on a potential shared pathophysiology tied to mast cell activity and neurogenic inflammation that may link pruritus and chronic cough (CC), this study, leveraging the All of Us database, examines the association between the two conditions.

MATERIALS AND METHODS:

A nested case-control comparison was used to examine the association, identifying cases with SNOMED codes 418363000 (pruritus) and 68154008 (CC). Matching was performed on a 1:4 ratio by age, sex, and ethnicity using the MatchIt package in R, followed by maximum likelihood method to estimate odds ratios (ORs) and 95% confidence intervals from 2x2 contingency tables.

RESULTS:

CC patients (n = 2,388) were more than twice as likely to be diagnosed with pruritus (OR: 2.65) and pruritus patients (n = 22,496) were more than twice as likely to be diagnosed with CC (OR: 2.57), than respective matched controls.

CONCLUSIONS:

These results highlight the potential bidirectional relationship between CC and pruritus, suggesting possible shared immune and neural pathways. Treatments like difelikefalin and nalbuphine that modulate these pathways, alongside P2X3 targeting agents, are emerging as potential therapeutic approaches for itch and chronic cough given the possible interconnected pathophysiology. This study's insights into the associations between pruritus and CC may pave the way for targeted therapeutic strategies that address their shared mechanisms.

18 Oct 2024·JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Alternative Reinforcers Enhance the Effects of Opioid Antagonists, but Not Agonists, on Oxycodone Choice Self-Administration in Nonhuman Primates.

Article

Author: de Moura, Fernando B ; Kohut, Stephen J

Clinical reports suggest that the most effective strategies for managing opioid use disorder comprise a comprehensive treatment program of both pharmacological and nonpharmacological approaches. However, the conditions under which these combinations are most effective are not well characterized. This study examined whether the presence of an alternative reinforcer could alter the efficacy of Food and Drug Administration-approved opioid antagonist or agonist medications, as well as the nonopioid flumazenil, in decreasing oxycodone choice self-administration in nonhuman primates. Adult squirrel monkeys (n = 7; four females) responded under concurrent second-order fixed-ratio (FR)-3(FR5:S);TO45s schedules of reinforcement for intravenous oxycodone (0.1 mg/kg) or saline on one lever and 30% sweetened condensed milk or water on the other. Doses of naltrexone (0.00032-1.0 mg/kg), nalbuphine (0.32-10 mg/kg), buprenorphine (0.0032-0.032 mg/kg), methadone (0.32-1.0 mg/kg), or flumazenil (1-3.2 mg/kg) were administered intramuscularly prior to oxycodone self-administration sessions that occurred with either milk or water as the alternative. Naltrexone, a μ-opioid receptor antagonist, was >30-fold more potent when milk was available compared with water and abolished oxycodone intake (injections/session) while concomitantly increasing milk deliveries at the highest dose tested. Pretreatment with the low-efficacy μ-agonist nalbuphine was most effective in the presence of milk compared with water, decreasing oxycodone preference to <50% of control values. The higher efficacy μ-agonists, methadone and buprenorphine, and the benzodiazepine antagonist flumazenil did not appreciably alter the reinforcing potency of oxycodone under either condition. These results suggest that antagonist medications used in combination with alternative reinforcers may be an effective strategy to curtail opioid abuse-related behaviors. SIGNIFICANCE STATEMENT: Clinical treatment programs for opioid use disorder use a combination of pharmacological and nonpharmacological approaches. However, the conditions under which these combinations are most effective have not been fully characterized. This study examined whether the effectiveness of μ-opioid medications to decrease oxycodone self-administration is altered in the presence of an alternative reinforcer. The results suggest that alternative reinforcers enhance the effects of antagonist or low-efficacy partial agonists, suggesting they may be a more effective strategy to curtail opioid use.

17 Oct 2024·JOURNAL OF PHARMACEUTICAL SCIENCES

Physical Compatibility and Chemical Stability of Bupivacaine, Epinephrine, and Nalbuphine in 0.45% Sodium Chloride, 0.9% Sodium Chloride, or Plasma-Lyte A.

Article

Author: Kumar, Virender ; Reinert, Justin P ; Mihigo, Zachary SengerGladys Uwera ; Baki, Gabriella ; Howard, Mitchell S ; Churchwell, Mariann D

PURPOSE:

To evaluate the physical compatibility and chemical stability of the combination of bupivacaine, epinephrine, and nalbuphine when in mixed in 0.45% sodium chloride, 0.9% sodium chloride, or Plasma-Lyte A.

METHODS:

Bupivacaine 0.5% (15 mL), epinephrine 1 mg/mL (0.15 mL), and nalbuphine 10 mg/mL (0.5 mL) were combined to prepare three distinct admixtures with 0.45% sodium chloride, 0.9% sodium chloride, or Plasma-Lyte A. Visual inspection, spectrophotometric analysis, pH evaluation, and high-performance liquid chromatography tests were conducted at hours 0, 1, 5, 8, and 24. Samples were stored in ambient room light at room temperature.

RESULTS:

There were no demonstrable changes identified in any of the samples with regards to visual changes, spectrophotometric absorbance, or pH. In each studied fluid, the remaining drug concentrations were an average of 100.92% bupivacaine, 95.8% epinephrine, and 100.02% nalbuphine.

CONCLUSIONS:

The combination of bupivacaine, epinephrine, and nalbuphine was found to be physically compatibility and chemically stable for a period of 24 hours at room temperature.

News (Medical) associated with Nalbuphine Hydrochloride

21 Oct 2024

·www.prnewswire.com

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn., Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025. "We are happy to have completed enrollment for our Phase 2a RIVER trial for the treatment of RCC," said Jennifer Good, President and CEO of Trevi Therapeutics. "RCC impacts approximately 2-3 million adults in the U.S. and with no approved treatment options, there is a large unmet need for new therapies that address cough hypersensitivity. We look forward to reporting the topline results for RIVER early next year and building on the positive results we have seen in studying chronic cough in IPF." Phase 2a Trial Design: Refractory Chronic Cough Improvement Via Nal ER (RIVER) The Phase 2a RIVER trial is a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover study designed to evaluate the efficacy, safety, tolerability and dosing of Haduvio for the treatment of RCC. The trial is being conducted at multiple sites in the United Kingdom and Canada. The primary endpoint of the trial is a mean change in 24-hour cough frequency in the overall population as determined using an objective cough monitor. Based on the screening results, the study will enroll patients into one of two subgroups: 10-19 coughs/hour (moderate 24-hour cough frequency) and ≥20 coughs/hour (high 24-hour cough frequency). The trial will also explore secondary endpoints, including patient-reported outcome measures for cough frequency and severity. The trial was designed to enroll approximately 60 adult patients. About Refractory Chronic Cough (RCC) Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) or where no underlying condition exists. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is highly disruptive and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release (ER)) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe refractory chronic cough. There are also no approved therapies for RCC in the U.S. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trevi's expectation of reporting topline data from Trevi's Phase 2a RIVER trial in the first quarter of 2025. Risks that contribute to the uncertain nature of the forward-looking statements include uncertainties regarding the success and timing of Trevi's product candidate development activities, including its ongoing clinical trials, uncertainties regarding Trevi's ability to execute on its strategy, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact Katie Barrett Trevi Therapeutics, Inc. 203-304-2499 [email protected] Media Contact Rosalia Scampoli 914-815-1465 [email protected] SOURCE Trevi Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

$Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough$

Phase 2

15 Oct 2024

·www.prnewswire.com

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

NEW HAVEN, Conn., Oct. 15, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November. 3rd Chief Commercial Officer Summit October 23-24, 2024, Philadelphia, PA Oral Presentation: Commercial's Role in Clinical Trial Recruitment Presentation: October 23, 1:30pm EDT Trevi Representative: Farrell Simon, Chief Commercial Officer Register here BIO-Europe November 4-6, 2024, Stockholm Sweden Trevi Representative: Farrell Simon, Chief Commercial Officer Register here Stifel 2024 Healthcare Conference November 18-19, 2024, New York, NY Corporate Presentation: November 18, 11:30am EDT Trevi Representatives: Jennifer Good, President and CEO, Lisa Delfini, Chief Financial Officer Register here to watch the live presentation About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is an extended-release (ER) dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough. Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe refractory chronic cough. There are also no approved therapies for RCC in the U.S. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Investor Contact Katie Barrett Trevi Therapeutics, Inc. 203-304-2499 [email protected] Media Contact Rosalia Scampoli 914-815-1465 [email protected] SOURCE Trevi Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

03 Oct 2024

·www.prnewswire.com

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) study dosing complete; topline results expected in December 2024 NEW HAVEN, Conn., Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today provided updates on its clinical development programs. "We are excited to report these important clinical milestones that mark an impending data-rich period for Trevi's Haduvio," said Jennifer Good, President and CEO of Trevi Therapeutics. "Chronic cough in IPF is one of the most difficult-to-treat cough conditions where antifibrotics have not shown a benefit. We believe the centrally and peripherally acting mechanism of Haduvio uniquely positions it to work throughout the cough reflex arc and potentially offer relief for this important unmet need in IPF." Clinical Updates The Phase 2b CORAL trial for the treatment of chronic cough in patients with IPF has enrolled 50% of the targeted study enrollment, which is the number of patients needed for the pre-specified sample size re-estimation (SSRE). The SSRE will be performed once the last of these patients complete the six weeks of treatment. The outcome of the SSRE result is expected in December 2024. The three potential SSRE outcomes are: maintain current sample size (N=160), upsize within a pre-specified range, or evaluate for futility. Assuming no adjustments are made to the sample size, topline results are expected in the first half of 2025. The Human Abuse Potential (HAP) study completed dosing. Topline results are expected in December 2024. The Phase 2a RIVER trial for the treatment of RCC has enrolled the planned sample size but remains open to allow for additional enrollment in both arms to approximate the stratification targets. Topline results are now expected in the first quarter of 2025. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is an extended-release (ER) dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for a synergistic antitussive effect to treat chronic cough. Parenteral nalbuphine is not scheduled by the U.S. Drug Enforcement Agency. The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to 10% of the adult population, and Haduvio's expansion into RCC has the potential to reach patients suffering from moderate to severe refractory chronic cough. There are also no approved therapies for RCC in the U.S. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trevi's business plans and objectives, including future plans or expectations for Haduvio and plans and timing with respect to clinical trials, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success and timing of Trevi's product candidate development activities, including its ongoing clinical trials; the risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials in the same or a different indication; uncertainties regarding Trevi's ability to execute on its strategy; uncertainties with respect to regulatory authorities' views as to the data from Trevi's clinical trials and next steps in the development path for Haduvio in the United States and foreign countries, uncertainties inherent in estimating Trevi's cash runway, future expenses and other financial results, including Trevi's ability to fund future operations, including clinical trials, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact Katie Barrett Trevi Therapeutics, Inc. 203-304-2499 [email protected] Media Contact Rosalia Scampoli 914-815-1465 [email protected] SOURCE Trevi Therapeutics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

100 Deals associated with Nalbuphine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00843	Nalbuphine Hydrochloride	N02AF02	DB00844

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	US	Endo Operations Ltd.	15 May 1979
Pain	US	Endo Operations Ltd.	15 May 1979

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Analgesia	Phase 3	CN	Yichang Humanwell Pharmaceuticals Co., Ltd.	09 Oct 2023
prurigo nodularis	Phase 3	US	Trevi Therapeutics, Inc.	01 Mar 2015
prurigo nodularis	Phase 3	DE	Trevi Therapeutics, Inc.	01 Mar 2015
prurigo nodularis	Phase 3	PL	Trevi Therapeutics, Inc.	01 Mar 2015
Pruritus	Phase 3	DE	Trevi Therapeutics, Inc.	01 Mar 2015
Uremic pruritus	Phase 3	US	Trevi Therapeutics, Inc.	01 Jun 2014
Uremic pruritus	Phase 3	PL	Trevi Therapeutics, Inc.	01 Jun 2014
Uremic pruritus	Phase 3	RO	Trevi Therapeutics, Inc.	01 Jun 2014
Cough	Phase 2	AU	Trevi Therapeutics, Inc.	06 Feb 2024
Cough	Phase 2	CL	Trevi Therapeutics, Inc.	06 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05041270 (ZU-IRB#:7045-15-8-2021, Pubmed \| BMC Anesthesiol)	Not Applicable	-	69	Bupivacaine + Normal Saline	rtzbugdgwq(jnswztqpqj) = yiqrrzgdwr dckigeexxm (gjtdcwmbsq ) View more	Positive	06 Dec 2023
				Bupivacaine + Nalbuphine	rtzbugdgwq(jnswztqpqj) = whbejposme dckigeexxm (gjtdcwmbsq ) View more
NCT03497975 (PRISM, EADV2023) Manual	Phase 2/3	prurigo nodularis	247	Haduvio	qottliptel(lyylkaatca) = cavpagoptx iufhboznnn (vcljlgnafy ) View more	Positive	13 Oct 2023
NCT04030026 (CANAL, Corporate Publications) Manual	Phase 2	Idiopathic Pulmonary Fibrosis \| Chronic cough	38	Haduvio	gysdokkomp(jtxoaxpjzp) = ohchjjolkt cdskaeqsak (juojoabxsa ) View more	Positive	19 Sep 2022
				Placebo	gysdokkomp(jtxoaxpjzp) = isgqqqogre cdskaeqsak (juojoabxsa ) View more
NCT03059511 (Pubmed)	Phase 1	Jaundice, Neonatal	52	Intranasal nalbuphine	smqapltvoh(ltmyvejrij) = rydignosku muwoogryxh (iklyqrsifb )	-	13 Sep 2022
				Intravenous nalbuphine	smqapltvoh(ltmyvejrij) = khhevxpumv muwoogryxh (iklyqrsifb )
NCT03497975 (PRISM study, EADV2022)	Phase 2/3	prurigo nodularis	-	Oral Nalbuphine Extended-Release 162 mg	stmzwtcbqe(oaunyxzpzy) = unubkolrsn zjqtuakvcl (wdfqtzddhy )	Positive	07 Sep 2022
				Placebo	stmzwtcbqe(oaunyxzpzy) = vxwdobwcik zjqtuakvcl (wdfqtzddhy )
ERS2022	Phase 2	Idiopathic Pulmonary Fibrosis	45	NAL ER 27 mg once daily	zdiuugjpiy(fpjcqgxzmm) = ujoymoryjs wqlybtatgn (cosdyptjjz )	Positive	04 Sep 2022
NCT03497975 (PRISM, Corporate Publications) Manual	Phase 2/3	prurigo nodularis	344	Haduvio	ghfmfdumgl(gjxtslhaue) = qzssdqccrr iqjysrbaow (bpcxpxwzer ) View more	Positive	29 Jun 2022
				Placebo	ghfmfdumgl(gjxtslhaue) = zdbyycwumr iqjysrbaow (bpcxpxwzer ) View more
NCT04030026 (CANAL, Biospace) Manual	Phase 2	Idiopathic Pulmonary Fibrosis \| Chronic cough	26	Haduvio	ybbgdzawsv(regmfwbvwg) = eiwtrxorvu tkivbznmju (dzrrmoztcj )	Positive	24 Feb 2022
				Placebo	ybbgdzawsv(regmfwbvwg) = gcvfnwdfbr tkivbznmju (dzrrmoztcj )
NCT02174432 (CTgov)	Phase 2/3	prurigo nodularis	36	nalbuphine HCl ER	inxlzfnpmx(mljmolxldj) = ovsiebjndt njtdrrvbqf (wzmmtsikde, ngdvecjusr - xhrawarnva) View more	-	23 Oct 2020
NCT02143973 (CTgov)	Phase 2/3	Uremic pruritus	167	nalbuphine HCl ER	uwbdpuaiqr(mnygktxmlu) = cvrfzxanwn auiuhxjtrx (loqqhfrtob, ptcvonkdau - iokhqbadei) View more	-	07 Sep 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis